Voruciclib - CISMeF

Preferred Label : Voruciclib;

NCIt synonyms : 2-(2-Chloro-4-(trifluoromethyl)phenyl)-5,7-dihydroxy-8-((2R,3S)-2-(hydroxymethyl)-1-methylpyrrolidin-3-yl)-4H-1-benzopyran-4-one;

NCIt definition : A cyclin-dependent kinase (CDK) inhibitor with potential antineoplastic activity. Upon administration, voruciclib selectively inhibits cyclin-dependent kinase 4 (CDK4) and 6 (CDK6). This inhibits retinoblastoma (Rb) protein phosphorylation early in the G1 phase, which prevents CDK-mediated G1-S phase transition and leads to cell cycle arrest. This suppresses DNA replication and decreases tumor cell proliferation. CDK4 and 6 are serine/threonine kinases that are upregulated in many tumor cell types and play a key role in the regulation of cell cycle progression.;

UNII : W66XP666AM;

InChIKey : MRPGRAKIAJJGMM-OCCSQVGLSA-N;

CAS number : 1000023-04-0;

Molecule name : P1446A-05;

NCI Metathesaurus CUI : CL539514;

Détails

Origin ID

C141430;

UMLS CUI

C4683812;

Automatic exact mappings (from CISMeF team)
- voruciclib [MeSH concept]
Currated CISMeF NLP mapping
- voruciclib [MeSH Supplementary Concept]
Semantic type(s)
- Organic Chemical [UMLS semantic type]
- Pharmacologic Substance [UMLS semantic type]
UMLS correspondences (same concept)
- voruciclib [MeSH Supplementary Concept]
concept_is_in_subset
- CTRP Agent Terminology [NCIt concept]
- CTRP Terminology [NCIt concept]
- FDA Established Names and Unique Ingredient Identifier Codes Terminology [NCIt concept]
- NCI Drug Dictionary Terminology [NCIt concept]
- NCIt Antineoplastic Agent Terminology [NCIt concept]
has_target
- Cyclin-Dependent Kinase 4 [NCIt concept]
- Cyclin-Dependent Kinase 6 [NCIt concept]

Position du mot-clé dans l'(les) arborescence(s) :

Vous pouvez consulter :

recommendations
documents concerning education
documents for patients